<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00951301</url>
  </required_header>
  <id_info>
    <org_study_id>07-007749</org_study_id>
    <nct_id>NCT00951301</nct_id>
  </id_info>
  <brief_title>Evaluate Use of Mangosteen Juice Added to Usual Care in Reducing Risk of Recurrent Atrial Fibrillation</brief_title>
  <acronym>MRI-AF</acronym>
  <official_title>Mangosteen Effects on Inflammatory Markers in Atrial Fibrillation Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being done to see if the addition of mangosteen juice to standard medical care&#xD;
      will reduce the risk of atrial fibrillation (AF) recurrence following direct current (DC)&#xD;
      cardioversion. The study will also look at the effects the mangosteen juice may have on&#xD;
      biomarkers of inflammation and endothelial cell dysfunction (the tissue lining the arteries&#xD;
      does not function properly).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Mangosteen Effects on Inflammatory Markers in Atrial Fibrillation Trial is a study designed&#xD;
      to test the primary hypothesis that a dietary supplement (Mangosteen) containing&#xD;
      anti-inflammatory and anti-oxidant properties may effect the measured levels of inflammatory&#xD;
      biomarkers. Secondarily, this study will compare the attenuation of markers of endothelial&#xD;
      cell dysfunction including endothelial progenitor cells (EPCs), clinical levels of&#xD;
      anticoagulation (INR), digoxin, lipids, and glycosylated hemoglobin (Hgb A1c), quality of&#xD;
      life measurements, AF recurrences, and associated levels of inflammatory markers with those&#xD;
      experiencing recurrent AF between the mangosteen group and the placebo group.&#xD;
&#xD;
      This trial will randomize 250 patients presenting to the Mayo Clinic Cardioversion Unit over&#xD;
      one year to two groups including a mangosteen supplemented group versus a control group with&#xD;
      placebo juice. Patients will be enrolled who have a history of paroxysmal, persistent, or&#xD;
      longstanding persistent atrial fibrillation and excluded if they have a history of recent&#xD;
      surgery, myocardial infarction, infection, collagen vascular disease with active&#xD;
      inflammation, or thyroid disease. Furthermore, patients already on corticosteroids will be&#xD;
      excluded. Patients will be evaluated at enrollment and followed at 3 months and 6 months with&#xD;
      repeat ECG, laboratory testing of inflammatory biomarkers and endothelial function, as well&#xD;
      as quality of life questions.&#xD;
&#xD;
      The trial will track the effect of natural juices containing anti-inflammatory and&#xD;
      anti-oxidant properties on inflammatory markers, endothelial progenitor cells, and quality of&#xD;
      life. This trial will attempt to determine if any dietary supplement effects to inflammatory&#xD;
      markers correlate with the rate of recurrent AF in each of the two groups.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Significantly lower accrual rate than anticipated, time constraints.&#xD;
  </why_stopped>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Test the hypothesis that the addition of mangosteen juice as a dietary supplement may reduce the measured levels of inflammatory biomarkers interleukin 1, interleukin 6, C-reactive protein (CRP), and tumor necrosis factor alpha (TNF a) etc).</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>attenuation of markers of endothelial cell dysfunction including endothelial progenitor cell (EPCs).</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical levels of anticoagulation (INR), digoxin, CBC, lipids, and glycosylated hemoglobin (Hgb A1c).</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AF recurrence rates between the mangosteen group and the placebo group</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Associated levels of inflammatory markers with those experiencing recurrent AF</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">143</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>mangosteen juice</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>subjects randomized 1:1 to this arm will receive juice containing the mangosteen ingredient</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo juice</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>subjects randomized 1:1 to this arm will receive specially prepared juice not containing mangosteen ingredient</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mangosteen juice</intervention_name>
    <description>6 ounces of juice containing mangosteen taken twice daily, AM and PM, for 6 months duration of study participation.</description>
    <arm_group_label>mangosteen juice</arm_group_label>
    <other_name>Xango juice</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo juice</intervention_name>
    <description>6 ounces of specially prepared juice not containing mangosteen taken twice daily, AM and PM, for 6 months duration of the study participation.</description>
    <arm_group_label>placebo juice</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Candidates for this study must meet all of the following criteria:&#xD;
&#xD;
               -  Age &gt;18 years&#xD;
&#xD;
               -  Documented atrial fibrillation with a clinically indicated cardioversion.&#xD;
&#xD;
               -  Anticoagulation with therapeutic INR or PTT as per Mayo Clinic cardioversion&#xD;
                  guidelines.&#xD;
&#xD;
               -  Provision of written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects will be excluded if any of the following conditions apply:&#xD;
&#xD;
               -  Presence of atrial fibrillation secondary to a reversible cause such as&#xD;
                  thyrotoxicosis or alcohol use&#xD;
&#xD;
               -  Myocardial infarction within 1 month, CABG or cardiac surgery including surgical&#xD;
                  maze or AF radiofrequency ablation within the past 3 months&#xD;
&#xD;
               -  Presence of an implanted pacemaker, atrial defibrillator, or ventricular&#xD;
                  defibrillator&#xD;
&#xD;
               -  History of bleeding diathesis or coagulopathy&#xD;
&#xD;
               -  Known atrial thrombus or contra-indication to cardioversion&#xD;
&#xD;
               -  Active infection or collagen vascular disease with active inflammation&#xD;
&#xD;
               -  Current use of corticosteroids&#xD;
&#xD;
               -  Gastrointestinal (GI) or genitourinary bleed within the past six months requiring&#xD;
                  transfusion&#xD;
&#xD;
               -  Concomitant medical illness (i.e., cancer, congestive heart failure) that may&#xD;
                  preclude protocol compliance, confound data interpretation or limit&#xD;
                  life-expectancy to less than one year&#xD;
&#xD;
               -  Known allergy to juice components&#xD;
&#xD;
               -  Inability or refusal to cooperate with study procedures&#xD;
&#xD;
               -  Unsuccessful cardioversion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brent A Bauer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <study_first_submitted>July 31, 2009</study_first_submitted>
  <study_first_submitted_qc>August 3, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 4, 2009</study_first_posted>
  <last_update_submitted>March 14, 2016</last_update_submitted>
  <last_update_submitted_qc>March 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Brent A. Bauer</investigator_full_name>
    <investigator_title>PI</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

